Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.66 |
| ▸ | AKT1 | P31749 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 8/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.60 |
| ▸ | FYN | P06241 | 4/20 | 0.60 |
| ▸ | PRKACA | P17612 | 3/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.60 |
| ▸ | CSK | P41240 | 3/20 | 0.60 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.60 |
| ▸ | CDK2 | P24941 | 2/20 | 0.60 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.60 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.60 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.60 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785884 | 0.88 | SRC (0.74) | SRCAKT1ABL1RIPK2FYN | |
| SCHEMBL1964152 | 0.87 | SRC (0.66) | SRCAKT1ABL1RIPK2FYN | |
| SCHEMBL1964244 | 0.86 | SRC (0.75) | SRCAKT1ABL1RIPK2FYN | |
| SCHEMBL409554 | 0.86 | SRC (0.65) | SRCAKT1ABL1RIPK2FYN | |
| SCHEMBL13019703 | 0.86 | SRC (0.65) | SRCAKT1ABL1RIPK2FYN | |
| SCHEMBL13063870 | 0.85 | SRC (0.67) | SRCAKT1ABL1RIPK2FYN | |
| SCHEMBL1961935 | 0.84 | SRC (0.62) | SRCAKT1ABL1RIPK2FYN | |
| SCHEMBL1962110 | 0.82 | SRC (0.66) | SRCAKT1ABL1RIPK2FYN | |
| SCHEMBL12551738 | 0.81 | SRC (0.69) | SRCAKT1ABL1RIPK2FYN | |
| SCHEMBL1318810 | 0.81 | SRC (0.79) | SRCAKT1ABL1RIPK2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRx PHARMACEUTICALS, INC (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | SNCA, PARK7, PINK1 | SRC 3123/4885AKT1 1576/4885ABL1 2641/4885 |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | SRC 1332/4885AKT1 968/4885ABL1 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.